A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT FDA Advisory Nos. 2026 0001 to 2026 0015 DivinaLaw RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica Dihexa (8mg) 30 Tablets MEDICA DEPOT FDA Drug Approval Decisions Expected in May 2026 MPR